A 25-year-old woman with type 2 diabetes and liver disease

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

A 25-year-old woman with type 2 diabetes and liver disease. / Junker, Anders Ellekær; Gluud, Lise Lotte; Pedersen, Jens; Langhoff, Jill Levin; Holst, Jens Juul; Knop, Filip Krag; Vilsbøll, Tina.

In: Case Reports in Gastroenterology, Vol. 8, No. 3, 2014, p. 398-403.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Junker, AE, Gluud, LL, Pedersen, J, Langhoff, JL, Holst, JJ, Knop, FK & Vilsbøll, T 2014, 'A 25-year-old woman with type 2 diabetes and liver disease', Case Reports in Gastroenterology, vol. 8, no. 3, pp. 398-403. https://doi.org/10.1159/000369968

APA

Junker, A. E., Gluud, L. L., Pedersen, J., Langhoff, J. L., Holst, J. J., Knop, F. K., & Vilsbøll, T. (2014). A 25-year-old woman with type 2 diabetes and liver disease. Case Reports in Gastroenterology, 8(3), 398-403. https://doi.org/10.1159/000369968

Vancouver

Junker AE, Gluud LL, Pedersen J, Langhoff JL, Holst JJ, Knop FK et al. A 25-year-old woman with type 2 diabetes and liver disease. Case Reports in Gastroenterology. 2014;8(3):398-403. https://doi.org/10.1159/000369968

Author

Junker, Anders Ellekær ; Gluud, Lise Lotte ; Pedersen, Jens ; Langhoff, Jill Levin ; Holst, Jens Juul ; Knop, Filip Krag ; Vilsbøll, Tina. / A 25-year-old woman with type 2 diabetes and liver disease. In: Case Reports in Gastroenterology. 2014 ; Vol. 8, No. 3. pp. 398-403.

Bibtex

@article{b3b97682cbc04d638b4a4a7b422eb8ab,
title = "A 25-year-old woman with type 2 diabetes and liver disease",
abstract = "A 25-year-old female nurse was referred to our diabetes outpatient clinic with poorly controlled type 2 diabetes, obesity and elevated liver function tests (LFTs). Following a liver biopsy she was diagnosed with non-alcoholic steatohepatitis (NASH) and liver fibrosis. Treatment with subcutaneous injections of the glucagon-like peptide-1 receptor (GLP-1R) agonist liraglutide was initiated. After 46 weeks of treatment the patient had lost 16 kg, glycemic control was excellent and LFTs had normalized. Repeat liver biopsy and ultrasound showed reduction in hepatic fat content and inflammatory cells. The biopsy no longer fulfilled the criteria for NASH. The liver biopsies did not express hepatic GLP-1Rs using quantitative polymerase chain reaction. Our case suggests that liraglutide may benefit patients with NASH.",
author = "Junker, {Anders Ellek{\ae}r} and Gluud, {Lise Lotte} and Jens Pedersen and Langhoff, {Jill Levin} and Holst, {Jens Juul} and Knop, {Filip Krag} and Tina Vilsb{\o}ll",
year = "2014",
doi = "10.1159/000369968",
language = "English",
volume = "8",
pages = "398--403",
journal = "Case Reports in Gastroenterology",
issn = "1662-0631",
publisher = "S Karger AG",
number = "3",

}

RIS

TY - JOUR

T1 - A 25-year-old woman with type 2 diabetes and liver disease

AU - Junker, Anders Ellekær

AU - Gluud, Lise Lotte

AU - Pedersen, Jens

AU - Langhoff, Jill Levin

AU - Holst, Jens Juul

AU - Knop, Filip Krag

AU - Vilsbøll, Tina

PY - 2014

Y1 - 2014

N2 - A 25-year-old female nurse was referred to our diabetes outpatient clinic with poorly controlled type 2 diabetes, obesity and elevated liver function tests (LFTs). Following a liver biopsy she was diagnosed with non-alcoholic steatohepatitis (NASH) and liver fibrosis. Treatment with subcutaneous injections of the glucagon-like peptide-1 receptor (GLP-1R) agonist liraglutide was initiated. After 46 weeks of treatment the patient had lost 16 kg, glycemic control was excellent and LFTs had normalized. Repeat liver biopsy and ultrasound showed reduction in hepatic fat content and inflammatory cells. The biopsy no longer fulfilled the criteria for NASH. The liver biopsies did not express hepatic GLP-1Rs using quantitative polymerase chain reaction. Our case suggests that liraglutide may benefit patients with NASH.

AB - A 25-year-old female nurse was referred to our diabetes outpatient clinic with poorly controlled type 2 diabetes, obesity and elevated liver function tests (LFTs). Following a liver biopsy she was diagnosed with non-alcoholic steatohepatitis (NASH) and liver fibrosis. Treatment with subcutaneous injections of the glucagon-like peptide-1 receptor (GLP-1R) agonist liraglutide was initiated. After 46 weeks of treatment the patient had lost 16 kg, glycemic control was excellent and LFTs had normalized. Repeat liver biopsy and ultrasound showed reduction in hepatic fat content and inflammatory cells. The biopsy no longer fulfilled the criteria for NASH. The liver biopsies did not express hepatic GLP-1Rs using quantitative polymerase chain reaction. Our case suggests that liraglutide may benefit patients with NASH.

U2 - 10.1159/000369968

DO - 10.1159/000369968

M3 - Journal article

C2 - 25606030

VL - 8

SP - 398

EP - 403

JO - Case Reports in Gastroenterology

JF - Case Reports in Gastroenterology

SN - 1662-0631

IS - 3

ER -

ID: 132046734